Related Experiment Video

Updated: Sep 20, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.1K

Pleiotropic effects of clopidogrel

Dawn S Kuszynski1,2, D Adam Lauver3

  • 1Department of Pharmacology and Toxicology, College of Veterinary Medicine, Michigan State University, 1355 Bogue Street, B336 Life Science, East Lansing, MI, USA.

Purinergic Signalling
|June 9, 2022
PubMed

Insights

Clopidogrel, an anti-thrombotic drug, works by blocking the P2Y12 receptor. This review explores its known effects and potential new actions mediated by its metabolites in various tissues.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Cardiovascular Medicine

Background:

  • Clopidogrel is a prodrug essential for treating thrombotic diseases.
  • Its anti-thrombotic effect stems from inhibiting the P2Y12 receptor on platelets.
  • P2Y12 receptors are present in various tissues beyond platelets.

Purpose of the Study:

  • To review the known P2Y12 receptor-mediated effects of clopidogrel.
  • To explore emerging non-P2Y12 receptor-mediated effects of clopidogrel and its metabolites.
  • To discuss clopidogrel's impact across different tissues.

Main Methods:

  • Literature review of clopidogrel's pharmacological actions.
  • Analysis of studies on clopidogrel metabolites and their biological activities.
  • Synthesis of findings on P2Y12 receptor-dependent and -independent effects.

Main Results:

  • Clopidogrel's primary action is P2Y12 receptor inhibition, crucial for anti-thrombotic therapy.
  • Non-hemostatic effects of clopidogrel have been observed in various tissues.
  • Understudied metabolites may mediate P2Y12 receptor-independent effects.

Conclusions:

  • Clopidogrel's therapeutic benefits are linked to P2Y12 inhibition.
  • Further research is needed to understand the non-P2Y12 receptor-mediated effects of clopidogrel and its metabolites.
  • These effects may have implications for clopidogrel's broader clinical applications and side effects.

Keywords:
Arterial thrombosisClopidogrelP2Y12Platelets

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.1K
Analyzing Platelet Subpopulations by Multi-color Flow Cytometry08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

431

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
656
Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
41.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
934
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.9K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
317
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K